Lawitz E, et al. - Researchers evaluated rusasvir in combination with uprifosbuvir, administered at a higher dose than that assessed in an earlier study, for its efficacy and safety in 282 treatment-naive or interferon (with or without ribavirin)-experienced participants with or without compensated cirrhosis. They administered ruzasvir 180 mg plus uprifosbuvir 450 mg once daily for 12 weeks to all the participants. Outcomes revealed high efficacy of the two-drug combination of ruzasvir 180 mg plus uprifosbuvir 450 mg for 12 weeks with good tolerability among participants infected with hepatitis C virus GT1, GT2, GT4, GT5, and GT6. The treatment was less efficacious in GT3-infected persons. Fatigue (7.8%) and headache (7.4%) were the most frequently cited drug-related adverse events.